Skip to main content

Biogen Value Stock - Dividend - Research Selection

Biogen

ISIN: US09062X1037 , WKN: 789617

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

Biogen is a global biopharmaceutical company focused on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases.

 

Our marketed products include TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA). We also have certain business and financial rights with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions, GAZYVA indicated for the treatment of CLL and follicular lymphoma and other potential anti-CD20 therapies under a collaboration agreement with Genentech, Inc. (Genentech), a wholly-owned member of the Roche Group (Roche Group).

 

We support our drug discovery and development efforts through the commitment of significant resources to discovery, research and development programs and business development opportunities, particularly within areas of our scientific, manufacturing and technical capabilities. For nearly two decades we have led in the research and development of new therapies to treat MS, resulting in our leading portfolio of MS treatments. Now our research is focused on additional improvements in the treatment of MS, such as the development of next generation therapies for MS, with a goal to reverse or possibly repair damage caused by the disease. We are also applying our scientific expertise to solve some of the most challenging and complex diseases, including Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis (ALS), and are employing innovative technologies to discover potential treatments for rare and genetic disorders, including new ways of treating diseases through gene therapy.

 

Our innovative drug development and commercialization activities are complemented by our biosimilar therapies that expand access to medicines and reduce the cost burden for healthcare systems. We are leveraging our manufacturing capabilities and know-how to develop, manufacture and market biosimilars through Samsung Bioepis, our joint venture with Samsung BioLogics Co. Ltd. (Samsung Biologics). Under this agreement, we are currently manufacturing and commercializing two anti-tumor necrosis factor (TNF) biosimilars in certain European Union (E.U.) countries.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Biogen (NASDAQ:BIIB) sheds US$697m, company earnings and investor returns have been trending downwards for past five years

2025-04-01
Generally speaking long term investing is the way to go. But that doesn't mean long term investors can avoid big...

Biogen : Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease by the European Commission

2025-04-01
TOKYO and CAMBRIDGE, Mass., April 1, 2025 - Eisai Co., Ltd. and Biogen Inc. announced today an update on the ongoing regulatory review of the Marketing Authorization Application for lecanemab as a...

Biogen Inc. stock underperforms Monday when compared to competitors

2025-03-31
Biogen Inc. stock underperforms Monday when compared to competitors

Biogen Inc. stock underperforms Friday when compared to competitors

2025-03-28
Biogen Inc. stock underperforms Friday when compared to competitors

ClearBridge Growth ESG Portfolios Q4 2024 Commentary

2025-03-28
A market broadening in the fourth quarter sparked by Donald Trump’s election victory and a further interest rate cut from the US Federal Reserve proved momentum-driven and short-lived.

Biogen Inc. stock underperforms Thursday when compared to competitors

2025-03-27
Biogen Inc. stock underperforms Thursday when compared to competitors

Biogen: Balancing Risks And Opportunities

2025-03-27
Biogen enhances its portfolio and margins amidst market challenges and competition. Click here to find out why BIIB stock is a Hold.

Lilly adds Alzheimer's to online offerings

2025-03-27
Eli Lilly on Thursdayexpanded its direct-to-consumer online platform LillyDirect toinclude telehealth providers to diagnose and care for patientswith Alzheimer's disease, potentially boosting sales...

Biogen Inc. stock outperforms competitors on strong trading day

2025-03-26
Biogen Inc. stock outperforms competitors on strong trading day

Biogen Inc. stock underperforms Tuesday when compared to competitors

2025-03-25
Biogen Inc. stock underperforms Tuesday when compared to competitors